title: [Clinical effects of tolvaptan for patients with stage 4-5 chronic kidney disease in cardiac surgery].
abstract: We report clinical effects of tolvaptan, a vasopressin V2 receptor antagonist, in cardiac surgery. Tolvaptan was administrated to 5 patients with non-dialysis dependent stage 4-5 chronic kidney disease (CKD) during an early postoperative stage. Tolvaptan increased urine output and improved respiratory function in all patients without causing hemodynamic deterioration. All patients were able to avoid initiating long-term hemodialysis during hospital stay. Tolvaptan was effective and safe after cardiac surgery for patients with severe CKD.
authors.affiliation: Department of Cardiovascular Surgery, Oosumi-Kanoya Hospital, Kanoya, Japan.
authors.forename: Manabu
authors.initials: M
authors.lastname: Sato
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Nakayama
authors.forename: Hiromitsu
authors.initials: H
authors.lastname: Kawasaki
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Mukae
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001552:Benzazepines / Q000627:therapeutic use*; D006348:Cardiac Surgical Procedures; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017483:Receptors, Vasopressin / Q000819:agonists*; D000077602:Tolvaptan
chemical_list: D001552:Benzazepines; D017483:Receptors, Vasopressin; D000077602:Tolvaptan